Hepatitis C: reviewing the options
Tom Wong and Samuel Lee 1 mention some extrahepatic manifestations of infection with hepatitis C virus (HCV), but they do not discuss the urticarias. Internists and primary care physicians need to be aware that several forms of urticaria can be associated with asymptomatic HCV infection.
The link between HCV and urticaria is controversial, 2 because various studies have failed to differentiate between acute urticaria, chronic urticaria and urticarial vasculitis, all of which have been proposed as being associated with HCV infection. The estimated prevalence of urticaria varies from 1.8% to 24%, and one case-control study disputed the association altogether.
2 The association with other hepatitis viruses is more certain. For example, electron microscopy was used to identify hepatitis B surface antigen-antibody complexes in cryoprecipitates taken from patients during the acute urticarial episode.
3
Immune-complex deposits of viral hepatitis can activate the complement system, which results in a serum-sickness-like syndrome, with arthritis, excruciating headache and urticaria (known as Caroli's triad).
4 Urticaria resolves on treatment with interferon, and more benefit is seen when urticarial vasculitis is associated with mixed essential cryoglobulinemia.
5
HCV testing should not be a routine screening test for all urticarias, but it is good clinical practice to consider viral marker studies in a patient with urticaria who presents with icterus or elevated transaminase levels (or both). The awareness that urticaria or urticarial vasculitis may be caused by hepatitis C is important, as early antiviral treatment can reduce significant morbidity and mortality. 4 Additional studies are now showing that steatosis is another independent predictor of sustained virological response in these patients.
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Interestingly, findings in patients with genotype 3 indicate that only metabolic (but not viral) steatosis is associated with lower sustained virological response. 6 Second, current evidence suggests that among patients with genotype 3, viral load is an important predictor of both sustained virological response 3, 4, 7, 8 and early virological response.
3 Moreover, for patients with genotype 2 or 3 and early virological response at week 4, shorter courses of therapy (12-16 weeks) were as effective as the recommended course of 24 weeks. 3, 7, 8 Whether patients with genotype 2 or 3 who have a high viral load and/or absence of early virological response (with or without advanced liver fibrosis) will benefit from longer treatment should be investigated in further clinical trials.
It therefore appears that both baseline histologic findings and viral load may be useful for tailoring treatment in certain subgroups of patients with genotype 2 or 3 in whom the standard duration of therapy might constitute overtreatment. 
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